I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
ADHD Therapeutics: A Primer
Recent Market Activity
ADHD Therapeutics Market Outlook
Factors Driving ADHD Therapeutics Market
Changes in Insurance Coverage
Addition of Formal Guidelines
Low Diagnosis Threshold
Advancements in Field of Medicine
Unmet Needs
Launch of Pipeline Drugs
Factors Inhibiting ADHD Therapeutics Market
Side Effects Related to Use of Stimulants to Treat ADHD
Under-diagnosis of ADHD Condition
Reduced Availability of Non-Stimulants in Certain Geographies
Competitive Landscape
Major ADHD Medications Available in the Market
ADHD Medications Approved by FDA
Patent Validity for Major ADHD Drugs
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
Alcobra Ltd. (Israel)
Amarantus Bioscience Holdings, Inc. (US)
Amedra Pharmaceuticals LLC (US)
Curemark, LLC. (US)
Eli Lilly and Company (US)
Intellipharmaceutics International, Inc. (US)
Janssen Global Services, LLC (US)
Mallinckrodt PLC (Ireland)
Mylan N.V. (The Netherlands)
Neos Therapeutics, Inc. (US)
Neurovance, Inc. (US)
Noven Pharmaceuticals, Inc. (US)
Pfizer Inc. (US)
Shire plc (Ireland)
Supernus Pharmaceuticals, Inc. (US)
Tris Pharma, Inc. (US)

3. MARKET TRENDS & DRIVERS
Biological Psychiatry Gaining Ground
Social Media Drives Heightened Awareness
Stimulants Dominate the Market but Non-Stimulants Inching Their
Way to Popularity
Robust Growth in Pediatric ADHD Therapeutic Market to Propel
Overall Market
Strategic Alliances

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets for Years
2012, 2020 & 2027

Table 4: World Current & Future Analysis for Stimulant by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Stimulant by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Stimulant by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-Stimulant by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Non-Stimulant by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Non-Stimulant by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Adult by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Adult by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Adult by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 13: World Current & Future Analysis for Children by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 14: World Historic Review for Children by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Children by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 16: World Current & Future Analysis for Retail Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Retail Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Retail Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Hospital Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 20: World Historic Review for Hospital Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospital Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 22: USA Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 23: USA Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 24: USA 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 25: USA Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 28: USA Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 29: USA Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: Canada Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 33: Canada 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 34: Canada Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 35: Canada Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 37: Canada Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

JAPAN
Table 40: Japan Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 42: Japan 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 43: Japan Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 46: Japan Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 47: Japan Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

CHINA
Table 49: China Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 51: China 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 52: China Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: China Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: China 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 55: China Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: China Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

EUROPE
Table 58: Europe Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany,
Italy, UK and Rest of Europe Markets for Years 2012, 2020 &
2027

Table 61: Europe Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 63: Europe 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 64: Europe Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 65: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

FRANCE
Table 70: France Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: France Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 72: France 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 73: France Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 74: France Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: France 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 76: France Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

GERMANY
Table 79: Germany Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 80: Germany Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 81: Germany 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 82: Germany Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 83: Germany Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Germany 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 85: Germany Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

ITALY
Table 88: Italy Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Italy Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 90: Italy 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 91: Italy Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Italy Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 93: Italy 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 94: Italy Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Italy Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: Italy 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 97: UK Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 98: UK Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 99: UK 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 100: UK Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: UK Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 102: UK 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Percentage Breakdown of Value Sales for Adult and Children for
the Years 2012, 2020 & 2027

Table 103: UK Current & Future Analysis for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 104: UK Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and Hospital Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 105: UK 15-Year Perspective for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Percentage Breakdown of Value Sales for Retail
Pharmacy and Hospital Pharmacy for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 106: Rest of Europe Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Drug Type - Stimulant and Non-Stimulant - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 107: Rest of Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Stimulant and Non-Stimulant Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 108: Rest of Europe 15-Year Perspective for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type -
Percentage Breakdown of Value Sales for Stimulant and
Non-Stimulant for the Years 2012, 2020 & 2027

Table 109: Rest of Europe Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Adult and Children - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 110: Rest of Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Demography -
Adult and Children Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 111: Rest of Europe 15-Year Perspective for Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Demography - Percentage Breakdown of Value Sales for Adult and
Children for the Years 2012, 2020 & 2027

Table 112: Rest of Europe Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by
Distribution Channel - Retail Pharmacy and Hospital Pharmacy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 113: Rest of Europe Historic Review for Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics by Distribution
Channel - Retail Pharmacy and